AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

Castaño-Díez S, López-Guerra M, Zugasti I, Calvo X, Schulz FI, Avendaño A, Mora E, Falantes J, Azaceta G, Ibáñez M, Chen T, Notario C, Amer N, Palomo L, Pomares H, Vila J, Bernal Del Castillo T, Jiménez-Vicente C, Esteban D, Guijarro F, Álamo J, Cortés-Bullich A, Torrecillas-Mayayo V, Triguero A, Mont-de Torres L, Carcelero E, Cardús A, Germing U, Betz B, Rozman M, Arenillas L, Zamora L, Díez-Campelo M, Xicoy B, Esteve J, Díaz-Beyá M

Open source

DOI
10.1182/bloodadvances.2024013648
Published
2025 Jan 14
Container
Blood advances
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2024013648,
  title = {AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.},
  author = {Castaño-Díez S and López-Guerra M and Zugasti I and Calvo X and Schulz FI and Avendaño A and Mora E and Falantes J and Azaceta G and Ibáñez M and Chen T and Notario C and Amer N and Palomo L and Pomares H and Vila J and Bernal Del Castillo T and Jiménez-Vicente C and Esteban D and Guijarro F and Álamo J and Cortés-Bullich A and Torrecillas-Mayayo V and Triguero A and Mont-de Torres L and Carcelero E and Cardús A and Germing U and Betz B and Rozman M and Arenillas L and Zamora L and Díez-Campelo M and Xicoy B and Esteve J and Díaz-Beyá M},
  year = {2025},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2024013648},
  url = {https://doi.org/10.1182/bloodadvances.2024013648}
}

RIS

TY  - JOUR
TI  - AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.
AU  - Castaño-Díez S
AU  - López-Guerra M
AU  - Zugasti I
AU  - Calvo X
AU  - Schulz FI
AU  - Avendaño A
AU  - Mora E
AU  - Falantes J
AU  - Azaceta G
AU  - Ibáñez M
AU  - Chen T
AU  - Notario C
AU  - Amer N
AU  - Palomo L
AU  - Pomares H
AU  - Vila J
AU  - Bernal Del Castillo T
AU  - Jiménez-Vicente C
AU  - Esteban D
AU  - Guijarro F
AU  - Álamo J
AU  - Cortés-Bullich A
AU  - Torrecillas-Mayayo V
AU  - Triguero A
AU  - Mont-de Torres L
AU  - Carcelero E
AU  - Cardús A
AU  - Germing U
AU  - Betz B
AU  - Rozman M
AU  - Arenillas L
AU  - Zamora L
AU  - Díez-Campelo M
AU  - Xicoy B
AU  - Esteve J
AU  - Díaz-Beyá M
PY  - 2025
JO  - Blood advances
DO  - 10.1182/bloodadvances.2024013648
UR  - https://doi.org/10.1182/bloodadvances.2024013648
ER  -

APA

S, C., M, L., I, Z., X, C., FI, S., A, A., E, M., J, F., G, A., M, I., T, C., C, N., N, A., L, P., H, P., J, V., T, B. D. C., C, J., D, E., F, G., J, Á., A, C., V, T., A, T., L, M. T., E, C., A, C., U, G., B, B., M, R., L, A., L, Z., M, D., B, X., J, E., & M, D. (2025). AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.. Blood advances. https://doi.org/10.1182/bloodadvances.2024013648

Source records